Skip to content

NeoGenomics NEO EBITDA margin

EBITDA margin at other companies

Labcorp Holdings logo
Labcorp HoldingsLH
15%+1.8pp
Quest Diagnostics logo
Quest DiagnosticsDGX
19.4%+0.6pp
Personalis, Inc. logo
Personalis, Inc.PSNL
-143.7%-918pp
Guardant Health logo
Guardant HealthGH
-37.8%-8.5pp
Natera, Inc. logo
Natera, Inc.NTRA
-11.1%+0.5pp
GeneDx Holdings logo
GeneDx HoldingsWGS
-9%

Other financials

Income statement

See full
Revenue$186.7M+11.1%
Gross profit$80.9M+10.4%
Operating income-$18.2M+34.4%
Net income-$17.1M+34.0%
EPS (diluted)-$0.13+35.0%

Balance sheet

See full
Cash & equivalents$146.1M-57.8%
Total debt$66.3M+5.3%
Total equity$828.8M-6.7%
Total assets$1.3B-15.9%

Cash flow

See full
Operating cash flow-$8.1M+67.9%
CapEx$5.0M+11.1%
Free cash flow-$13.1M+56.0%

Valuation

See full
Market cap$1.68B-21.0%
Enterprise value$1.6B-5.6%
P/S2.3×-0.9×

Profitability

See full
Gross margin43.2%-1.1pp
Operating margin-14.2%+1.1pp
Net margin-13.3%+2.4pp
FCF margin-4.9%

Returns & leverage

See full
Return on equity-11.6%+6.2pp
Debt / equity0.1×0.0×
Current ratio4.4×+2.4×

Where this comes from

Calculated from NeoGenomics’s reported figures.

Based on trailing twelve months.

The official record: NeoGenomics’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about NeoGenomics's ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NeoGenomics's EBITDA margin?
NeoGenomics (NEO) reported EBITDA margin of -5.3% in Q1 2026.
How has NeoGenomics's EBITDA margin changed year-over-year?
NeoGenomics's EBITDA margin decreased by 106.6% year-over-year, from -2.6% to -5.3%.
What is the long-term trend for NeoGenomics's EBITDA margin?
Over 4 years (2021 to 2025), NeoGenomics's EBITDA margin has grown at a -16.4% compound annual growth rate (CAGR), from -13.5% to -6.6%.
What does EBITDA margin mean?
EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.